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Abstract 
Objectives. This study was performed to investigate the prevalence and impact on survival of 
baseline calcific mitral stenosis (MS) in patients undergoing  transcatheter aortic valve 
replacement (TAVR) due to the presence of severe symptomatic aortic stenosis (AS).  
Methods. This retrospective study included 928 consecutive patients with severe, 
symptomatic AS undergoing TAVR in two institutions, from January 2012 to August 2016. 
Mean follow-up was 40.8±13.9 months.  
Results. Based on mean mitral gradients (MMG) at baseline, 3 groups were identified: normal-
mild, MMG<5 mmHg (n=737, 81.7%); moderate MMG5 and <10 mmHg (n=147, 16.3%); 
severe MMG10 mmHg (n=17, 1.9%). These latter were more frequently women, with a 
smaller body surface area, a higher prevalence of atrial fibrillation, chronic obstructive 
pulmonary disease and previous history of CABG/PCI. At baseline, patients with MMG10 
mmHg compared with 5 and <10 mmHg and normal patients exhibited a lower mitral valve 
area (2.4±0.94 vs 2.1±0.86 vs 1.5±0.44 cm2) a lower prevalence of MR2+ (5.9% vs 28.6% 
and 15.6%, p<0.0001), a higher prevalence of severe mitral annular calcium (70.6% vs 45.6% 
and 13.0%, p<0.0001) and a higher systolic pulmonary arterial pressure (50.6±12.1 vs 
47.2±14.5 and 41.6±14.4, p<0.0001). Despite the low prevalence of MMG10 mmHg, these 
patients experienced higher 5-year mortality compared to the other groups (adjusted Hazard 
Ratio: 2.91, 95% Confidence Interval [CI]:1.17-7.20, p=0.02). 
Conclusions. Severe calcific MS is uncommon in patients undergoing TAVR. However, its 
presence is associated with higher long-term mortality whereas moderate MS is not. The 
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presence of severe calcific MS might identify a subgroup of patients in whom a double valve 
intervention should be considered.  
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Introduction 
Degenerative aortic stenosis (AS) is characterized by calcific thickening and fusion of the aortic 
leaflets which often involves the mitral annulus and leaflets, particularly in the elderly 
population1-4 . In some patients, this leads to the concomitant presence of aortic and mitral 
stenosis (i.e. variously termed calcific, non-rheumatic, or degenerative mitral stenosis -MS). It 
has been reported that the prevalence of MS in patients with severe AS is around 10%5. 
Current guidelines on the management of patients with concomitant aortic and mitral stenosis 
recommend a double valve intervention when the disease is judged to be moderate or severe. 
Transcatheter aortic valve replacement (TAVR) is the new standard of care for patients with 
symptomatic severe AS who are deemed at intermediate or higher risk for surgical aortic valve 
replacement (SAVR). Because double valve replacement increases operative risk compared 
to SAVR alone, patients with severe AS and MS are almost always at least intermediate risk. 
In this population, data on the prevalence of MS and its role on survival are limited. A recent 
report from the TVT registry identified mitral valve area (MVA) as a predictor of mortality at 1-
year after TAVR6. So far this is the only available data on this topic, and it suffers from lack of 
long-term follow-up. Moreover, severe MS was defined by MVA < 1.5 cm2 derived from 
echocardiography or catheterization using various methods, which likely overestimated the 
proportion of patients in the severe MS group6. In this paper, using a different definition of MS 
based on resting mean mitral gradients (MMG), we sought to investigate the prevalence of MS 
in a cohort of TAVR patients from two centers and how the presence of MS impacted the 5-
year survival of this population.   
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Methods 
Study design 
We retrospectively examined 928 patients with severe symptomatic AS undergoing TAVR at 
Baylor Heart and Vascular Hospital (Dallas, TX) and The Heart Hospital Baylor Plano (Plano, 
TX) from January 2012 to August 2016. Baseline demographics, echocardiographic and 
procedural data were retrospectively collected and analyzed. For the purpose of this analysis, 
data from both medical centers were pooled and a joint database was created. Only patients 
with complete echocardiographic information at baseline and post-TAVR were considered for 
this analysis. Primary outcome was all-cause mortality at 5-years follow-up, which was 
obtained through querying the National Death Index. The study was approved by the Baylor 
Institutional Review Board. 
Two-dimensional echocardiography 
Transthoracic echocardiography was performed using a commercially available system (iE33 
or Epiq, Koninklijke Philips Electronics N.V.). Images of the standard parasternal and apical 
views were obtained with the patient in the left lateral decubitus position. Left ventricular (LV) 
dimensions and function, left atrium diameters were measured according to the current 
guidelines 7, 8.  
MR was evaluated pre- and post-TAVR on the basis of the integration of multiple parameters, 
including color Doppler jet area, vena contracta width, and effective regurgitant orifice area 
and regurgitant volume by proximal isovelocity surface area and volumetric methods and 
graded as no/trivial, mild, moderate, or severe per guideline recommendations9. MMG was 
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determined pre- and post-TAVR from the Doppler diastolic mitral flow; based on MMG at 
baseline, 3 groups of patients were identified normal-mild, MMG<5 mmHg; moderate MMG≥5 
and <10 mmHg; severe MMG≥10 mmHg 10. Mitral annular calcification (MAC) was defined by 
presence of echodense calcium deposits at the base of mitral leaflets between the left atrium 
and ventricle 11, 12. MAC location was specified as anterior and/or posterior. MAC grade was 
reported as none, mild (<25% of mitral annulus), moderate (25-50% of mitral annulus), severe 
(≥50% of mitral annulus). 
Statistical analysis 
Continuous variables were presented as mean±standard deviation. Categorical data were 
reported as frequencies and percentages. Differences in continuous variables between MMG 
groups were compared using the one-way analysis of variance (ANOVA) or the Mann-Whitney 
U-test, as appropriate. Differences in categorical variables between MMG groups were 
compared using the Chi-square test. Unadjusted, cumulative long-term mortality was 
compared across the three MMG groups using Kaplan-Meier approach and the log-rank test. 
Due to the small number of patients (n=17) in the largest MMG group, inclusion of additional 
covariates for adjustment would have been inappropriate due to the lack of adequate overlap 
in characteristics between comparison groups. Therefore, to adjust for potential confounding 
due to preoperative patient characteristics, we formed a risk-adjusted Cox Proportional 
Hazards time-to-mortality model by including the US-TAVR score (modeled using a three-knot 
restricted cubic spline function) as an adjustment covariate along with MMG group. The 
proportional hazards assumption was confirmed by the chi-squared test of the interaction 
between MMG group and survival time (p=0.67). For all tests, a p-value<0.05 was considered 
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statistically significant. Statistical analyses were performed using SPSS® software version 
20.0 (IBM, Armonk, NY, USA) 13 and SAS 9.4 (SAS Inc., Cary, NC).13. 
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Results 
Study Population 
During the study period from January 2012 to August 2016, a total of 928 patients underwent 
TAVR. Of those, complete echocardiographic and survival data were available for 901 patients 
(97%). Table 1 displays the baseline characteristics for the study population according to 
baseline MMG. The majority had normal-mild MMG (< 5 mmHg) at baseline (n=737, 81.7%); 
147 patients (16.3%) had a moderate increased MMG (≥5 and <10 mmHg), and only 17 
patients (1.9%) showed a baseline MMG≥10 mmHg. As shown in Table 1, patients with a 
baseline MMG ≥10 mmHg tend to be more frequently female (76.5% vs 41.5% and 72.15, 
p<0.0001) and smaller in body size (1.8±0.22 vs 1.9±0.25 and 1.8±0.25, p=0.001). Compared 
to patients with normal-mild MMG and to those with a moderate increase in MMG, those with 
baseline MMG≥10 mmHg showed a higher prevalence of atrial fibrillation (35.3% vs 32.7% 
and 22.4%, p=0.046), chronic obstructive pulmonary disease (47.1% vs 21.4% and 22.4%, 
p=0.041) and previous history of CABG/PCI (70.6% vs 50.2% and 36.7%, p=0.002). 
Procedural characteristics 
The three groups were similar for procedural characteristics apart from the use of smaller aortic 
valve prosthesis in the group of patients with baseline MMG≥10 mmHg (p<0.0001; Table 1).  
Echocardiographic characteristics 
As reported in Table 2, patients with baseline MMG≥10 mmHg showed higher LV ejection 
fraction compared to the other two groups (LVEF, 60.6±13.2 vs 53.7±13.1 and 58.5±13.1, 
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p<0.0001). This latter group also showed higher aortic valve mean gradients (47.8±10.8 vs 
43.8±13.4 and 48.8±16.4, p<0.0001) and peak velocity (4.6±0.5 vs 4.3±0.62 and 4.5±0.65, 
p=0.001). Consistently, they had higher mitral mean gradients (11.8±1.7 vs 2.3±1.0 and 
6.2±1.3, p<0.0001), smaller MVA (1.5±0.44 vs 2.4±0.94 and 2.1±0.86, p<0.0001) and a higher 
prevalence of severe MAC (64.7% vs 13.0% and 45.6%, p<0.0001), which was more 
frequently localized both on the anterior and posterior annulus (41.2% vs 11.7% and 31.7%, 
p<0.0001). Finally, patients with baseline MMG≥10 mmHg showed a significantly lower 
prevalence of MR≥2+ (5.9% vs 15.6% and 28.6%, p<0.0001) and a higher systolic pulmonary 
arterial pressure (sPAP, 50.6±12.1 vs 41.6±14.4 and 47.2±14.5, p<0.0001) compared to the 
other two groups. After TAVR, patients with baseline MMG≥10 mmHg showed a persistently 
higher LVEF (61.9±6.6 vs 54.8±11.9 and 56.9±10.6, p=0.012), slightly higher aortic mean 
gradient (10.2±5.4 vs 8.3±4.1 and 9.3±4.5, p=0.004). Patients starting with MMG≥10 mmHg 
also displayed higher MMG post-TAVR (8.7±4.5 vs 3.0±1.56 and 5.1±2.3, p<0.0001, Table 3). 
Outcomes 
As reported in Table 4, the three groups did not differ for any of the listed outcomes, apart from 
the prevalence of mitral valve interventions at follow-up which occurred more frequently in the 
group of patients with baseline MMG≥10 mmHg (5.9% vs 0.2% and 0.7%, p=0.003). 
Long-term Survival  
Figure 1 shows unadjusted Kaplan-Meier cumulative survival (with shaded 95% Confidence 
Intervals) and TAVR score risk-adjusted Hazard Ratios by Mitral Mean Gradient [(MMG): <5, 
5≤MMG<10, and MMG≥10] for 901 patients with complete MMG and follow-up data. There 
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were 102 total deaths matched with data from the National Death Index over 5 years (60 
months) of follow-up. The mean follow-up was 40.8±13.9 months. Those with a baseline 
MMG≥10 experienced nearly 3 times the risk of long-term mortality compared to those with 
baseline MMG<5 (TAVR-risk Adjusted HR: 2.91, 95% CI: 1.17-7.20, p=0.02). When the 
population was stratified according to MVA, no difference in long-term mortality was observed 
between patients with MVA> 1.5 cm2 and those with MVA≤1.5 cm2 (TAVR-risk Adjusted HR: 
1.08, 95% CI: 0.62-1.85, p=0.81, Figure 2). Mortality was additionally assessed by stratifying 
the population as follows: patients with baseline and post-TAVR MMG < 10 mmHg;  patients 
with baseline MMG < 10 mmHg  and post-TAVR MMG ≥10 mmHg; ;  patients with baseline 
MMG ≥ 10 mmHg  and post-TAVR MMG ≥10 mmHg; patients with baseline MMG ≥ 10 mmHg  
and post-TAVR MMG < 10 mmHg. Having a MMG ≥10 mmHg at baseline and post-TAVR was 
extremely rare (n=3) but portended a detrimental long-term survival (TAVR-risk Adjusted HR: 
7.09, 95% CI: 1.74-28.9, p=0.03, Figure 3). 
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Discussion 
To the best of our knowledge, this is the first registry assessing the prevalence and role on 
survival at 5-years after TAVR of MS. The main findings of this study are the following: 1.The 
prevalence of severe MS, defined as MMG ≥10 mmHg, in this cohort of severe AS patient is 
low, approximately 2%. 2. Patients with baseline MMG≥10 mmHg are frequently women, with 
a worse baseline risk profile compared to the other groups. 3. Despite the low prevalence of 
MMG≥10 mmHg prior to TAVR, patients in this group experience a nearly 3 times higher 
mortality at 5 years after the procedure compared to other groups.  
The prevalence of MS in patients with AS has been reported to be around 10% and generally 
the outcome of these patients is very poor once they develop symptoms5. The ACC/AHA 
guidelines for valve disease recommend double valve intervention in these cases, although it 
carries a high operative risk 2, 14. Moreover, mitral valve replacement in cases of MS with severe 
MAC might be particularly challenging with a high risk of post-operative paravalvular leakage 
and complications. The development of TAVR in the last decade has drastically reduced the 
operative risk and improved survival of high to intermediate-risk or inoperable patients, and 
might represent a valid alternative also for patients with concomitant MS. However, data about 
MS in the TAVR era are scarce. A recent report form the TVT registry documented that severe 
MS (as defined by a MVA ≤1.5 cm2) is a predictor of mortality and re-hospitalization for heart 
failure at 1-year after-TAVR6. In this study, the authors reported a prevalence of MS around 
3%, similar to what we found in our population (1.9%). However, this was based on site-
reported MVA using variable methodologies and MMG was not reported. Although the latest 
U.S. and European guidelines on valvular disease define MS based on MVA as measured by 
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planimetry, this recommendation is based on rheumatic heart disease15, 16. When the mitral 
valve is calcified, planimetry is limited by shadowing and blooming artifact 17 (Figure 4). MVA 
by pressure half-time is strongly affected by the net compliance of the LV and LA, which are 
altered in AS18. By defining calcific MS as MMG ≥ 10 mmHg, we selected a group with a high 
specificity for severe MS and elevated LA pressures at rest with normal heart rate (68.7±11.0 
bpm). Indeed, when we stratified our population according to MVA, the group with MS 
(MVA≤1.5 cm2, n=123) did not experience a higher mortality up to 5 years after TAVR 
compared to patients with MVA>1.5 cm2. Because MMG is flow and heart rate dependent, it is 
possible that more patients would have been classified as severe MS, had they undergone 
exercise testing; however; there was no clinical indication to do such in this population with 
severe symptomatic AS.  
As to why patients with MMG≥10 mmHg experience a poor prognosis compared to the other 
two groups, some hypothesis might be generated. Firstly, it is likely that in our population the 
etiology of MS is degenerative given the older age, the higher prevalence of atherosclerosis in 
this group, as testified by the higher prevalence of CAGB/PCI and the higher prevalence of 
severe MAC located both in the anterior and posterior annulus. In turn, the higher 
atherosclerotic burden could explain, at least in part, the worse outcome. Previous studies 
have reported that patients with calcification of the aortic and mitral annulus frequently have 
calcified LV outflow tract which independently predict post-TAVR aortic regurgitation19. 
Although the presence of post-TAVR paravalvular leak has been associated with worse 
outcomes, we did not find differences in its prevalence in our population. Additionally, the group 
of patients with MMG≥10 mmHg had a higher prevalence of atrial fibrillation and higher sPAP; 
if, on the one hand, both conditions might be a direct result of the severe MS, on the other 
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hand, it has been widely shown that their presence is a marker of impaired prognosis 13, 20, 21. 
Taken together these observation suggest that the increased baseline risk profile for patients 
with severe MS undergoing TAVR could potentially explain the increased rates of 5-year 
mortality. The result of this study indicate that patients with severe MS are a minority of those 
undergoing TAVR and that these patients experience a bad outcome at 5 years follow-up 
compared to patients with normal MMG. This does not mean that patients with severe AS and 
MS should not be offered a TAVR, but that such patients will need a more comprehensive 
approach that possibly includes the discussion and timing for mitral valve intervention. Indeed, 
with advances in transcatheter valve therapies, a percutaneous approach may become a 
viable alternative to conventional open heart surgery in selected high-risk patients with 
concomitant severe AS and MS. Further studies are certainly needed at this regard to prove a 
survival benefit of mitral valve intervention following TAVR in patients with concomitant severe 
MS. 
Limitations 
First, this study suffers from the intrinsic limitations of a retrospective design. Second, complete 
echocardiographic data were not available or not accurate for 2.9% of the population, which 
was therefore excluded from this analysis. Third, in this study we categorized MS according to 
MMG, which has the advantage of being a direct measurement, unlike calculated MVA derived 
from pressure half-time measurement or continuity equation. MVA by pressure half-time is 
prone to error resulting from LV/LA compliance and aortic regurgitation,10 both of which are 
common in TAVR patients. Direct planimetry of MVA is recommended in rheumatic MS, but is 
challenging in degenerative MS due to shadowing and blooming artifact from annular and 
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leaflet calcium. Although MMG is influenced by heart rate and cardiac output, a high value 
reflects elevated LA pressure which may limit symptomatic improvement after TAVR. All of the 
echocardiographic measurements of the included patients have been done at a heart rate < 
100 bpm; also, the group of patients with MMG≥10 mmHg showed the lower prevalence of 
MR≥2+, such the increased MMG cannot be explained by significant MR. Finally, the small 
number of patients with a MMG≥10 mmHg has to be acknowledged as a potential limitation of 
our study. 
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Figure Legend 
Figure 1. Kaplan-Meier curves for 5-year survival according to MMG. Unadjusted Kaplan-
Meier cumulative survival (with shaded 95% Confidence Intervals) and TAVR score risk-
adjusted Hazard Ratios by MMG (MMG<5, 5≤MMG<10, and MMG≥10) for 901 patients with 
complete MMG and follow-up data. 
Figure 2. Kaplan-Meier curves for 5-year survival according to MVA. Unadjusted Kaplan-Meier 
cumulative survival (with shaded 95% Confidence Intervals) and TAVR score risk-adjusted 
Hazard Ratios by Mitral Valve Area [(MVA): ≤1.5 cm2, MVA>1.5 cm2] for 890 patients with 
complete MVA and follow-up data. 
Figure 3. Kaplan-Meier curves for 5-year survival according to MMG. Unadjusted Kaplan-
Meier cumulative survival (with shaded 95% Confidence Intervals) and TAVR score risk-
adjusted Hazard Ratios by MMG (Both pre and post-TAVR MMG: <10, either pre and/or post-
TAVR MMG≥10)  for 901 patients with complete MMG and follow-up data. 
Figure 4. Examples of short-axis view of the mitral valve.  Quantification of the MVA by 
planimetry is compromised by the amount of calcium on the mitral annulus generating a 
blooming artifact and/or by the high acoustic thoracic impedance. 
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Table 1. Characteristics of the study population according to baseline mean mitral gradients (MMG). 
  MMG <5 
mmHg 
(n=737) 
MMG 5 to 10 
mmHg 
(n=147) 
MMG ≥ 10 
mmHg 
(n=17) 
p 
Baseline characteristics     
Age, yrs 81.4±7.9 81.2±8.3 79.5±8.8 0.613 
Female 306 (41.5) 106 (72.1) 13 (76.5) <0.0001 
Body Mass Index, Kg/m2 27.7±6.6 28.6±7.2 27.0±5.0 0.338 
Body Surface Area, m2 1.9±0.25 1.8±0.24 1.8±0.22 0.001 
STS score, % 7.7±4.3 8.0±4.3 8.9±5.8 0.469 
TAVR risk score, % 4.7±2.2 5.1±2.1 5.4±2.3 0.123 
Hypertension 638 (86.6) 125 (85.0) 14 (82.4) 0.793 
Hyperlipidemia  550 (74.6) 112 (76.2) 11 (64.7) 0.585 
Diabetes 286 (38.8) 65 (44.2) 8 (47.1) 0.392 
Chronic kidney disease 560 (76.0) 147 (75.5) 10 (58.8) 0.266 
End stage renal disease 25 (3.4) 5 (3.4) 0 (0) 0.742 
Coronary artery disease 537 (72.9) 95 (64.6) 14 (82.4) 0.079 
Peripheral artery disease 234 (31.8) 45 (30.6) 8 (47.1) 0.383 
COPD 158 (21.4) 33 (22.4) 8 (47.1) 0.041 
Atrial Fibrillation 241 (32.7) 33 (22.4) 6 (35.3) 0.046 
Previous CABG/PCI 370 (50.2) 54 (36.7) 12 (70.6) 0.002 
Previous CVA 151 (20.5) 29 (19.7) 4 (23.5) 0.929 
Permanent Pacemaker 156 (21.2) 29 (19.7) 2 (11.8) 0.605 
Procedural characteristics     
Type of Valve    0.333 
Balloon-expandable 304 (41.2) 51 (34.7) 7 (41.2)  
Self-expandable 433 (58.8) 96 (65.3) 10 (58.8)  
Approach    0.528 
Trans-femoral 654 (88.7) 127 (86.4) 14 (82.4)  
Trans-apical 55 (7.5) 13 8.8) 1 (5.9)  
Trans-aortic 23 (3.1) 5 (3.4) 2 (11.8)  
Subclavian 5 (0.7) 2 (1.4) 0 (0)  
Valve Size (mm)    <0.0001 
20 9 (1.2) 5 (3.4) 1 (5.9)  
23 137 (18.6) 52 (35.4) 6 (35.3)  
25 11 (1.5) 2 (1.4) 0 (0)  
26 257 (34.9) 59 (40.1) 5 (29.4)  
27 11 (1.5) 1 (0.7) 0 (0)  
29 242 (32.8) 25 (17.0) 5 (29.4)  
31 67 (9.1) 3 (2.0) 0 (0)  
34 3 (0.4) 0 (0) 0 (0)  
Balloon pre-dilatation 506 (68.7) 95 (64.6) 11 (64.7) 0.608 
Balloon post-dilatation 352 (47.8) 77 (52.4) 6 (35.3) 0.330 
Values are mean±SD, n (%). 
Abbreviations: CABG: coronary artery by-pass graft; COPD: chronic obstructive pulmonary disease; 
CVA: cerebrovascular accident; LVEF: left ventricle ejection fraction; PCI: percutaneous coronary 
intervention; SD: standard deviation. 
 
  
 26 
Table 2. Baseline echocardiographic findings according to baseline mean mitral gradients. 
  MMG <5 
mmHg 
(n=737) 
MMG 5 to 10 
mmHg 
(n=147) 
MMG ≥ 10 
mmHg 
(n=17) 
p 
Echocardiographic findings     
Heart Rate, bpm 68.2±13.4 77.4±7.9 68.7±11.0 0.154 
LVEF, % 53.7±13.1 58.5±12.1 60.6±13.2 <0.0001 
Stroke Volume Indexed, 
ml/beat/m2 
37.5±12.2 38.1±10.5 40.5±9.1 0.523 
Aortic valve mean gradient, 
mmHg 
43.8±13.4 48.8±16.4 47.8±10.8 <0.0001 
Aortic valve area, cm2 0.69±0.19 0.66±0.18 0.67±0.15 0.246 
Aortic peak velocity, m/sec 4.3±0.62 4.5±0.65 4.6±0.50 0.001 
Mitral valve mean gradient, 
mmHg 
2.3±1.0 6.2±1.3 11.8±1.7 <0.0001 
Mitral Valve Area, cm2 2.4±0.94 2.1±0.86 1.5±0.44 <0.0001 
Mitral annular calcium grade    0.001 
None 108 (14.7) 7 (4.8) 0 (0) <0.0001 
Mild  290 (39.3) 16 (10.9) 2(11.8) <0.0001 
Moderate 243 (33.0) 57 (38.8) 4 (23.5) <0.0001 
Severe 96 (13.0) 67 (45.6) 11 (64.7) <0.0001 
Mitral annular calcium location     
Anterior OR posterior 537 (88.3) 95 (68.3) 10 (58.8) <0.0001 
Anterior AND posterior 71 (11.7) 44 (31.7) 7 (41.2) <0.0001 
Mitral regurgitation ≥2+, % 115 (15.6) 42 (28.6) 1 (5.9) <0.0001 
Aortic regurgitation ≥2+, % 73 (9.9) 22 (15.0) 3 (17.6) 0.131 
Tricuspid regurgitation ≥2+, % 85 (11.5) 21 (14.3) 3 (17.6) 0.503 
Systolic Pulmonary Arterial 
Pressure, mmHg 
41.6±14.4 47.2±14.5 50.6±12.1 <0.0001 
Left atrial volume, ml 82.7±30.6 88.9±35.0 88.6±26.6 0.173 
Values are mean±SD, median (minimum-maximum), n (%). 
Abbreviations: LVEF: left ventricle ejection fraction. 
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Table 3. Post-TAVR echocardiographic findings according to baseline mean mitral gradients. 
  MMG <5 
mmHg 
(n=737) 
MMG 5 to 10 
mmHg 
(n=147) 
MMG ≥ 10 
mmHg 
(n=17) 
p 
Echocardiographic findings     
Heart Rate, bpm 73.6±12.6 75.7±12.7 72.3±8.5 0.135 
LVEF, % 54.8±11.9 56.9±10.6 61.9±6.6 0.012 
Stroke Volume Indexed, ml/beat/m2 22.9±19.1 25.2±16.8 26.2±18.1 0.309 
Aortic valve mean gradient, mmHg 8.3±4.1 9.3±4.5 10.2±5.4 0.004 
Aortic valve area, cm2 2.0±0.60 1.8±0.53 1.8±0.37 0.014 
Aortic peak velocity, m/sec 2.0±0.47 2.1±0.44 2.2±0.51 0.096 
Mitral valve mean gradient, mmHg 3.0±1.56 5.1±2.3 8.7±4.5 <0.0001 
Mitral regurgitation ≥2+, % 53 (9.3) 16 (10.9) 1 (5.9) 0.462 
Paravalvular Regurgitation ≥2+, % 27 (3.7) 10 (6.8) 1 (5.9) 0.315 
Left atrial volume, ml 87.4±30.6 92.4±32.9 76.0±33.9 0.575 
Values are mean±SD, median (minimum-maximum), n (%). 
Abbreviations: LVEF: left ventricle ejection fraction. 
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Table 4. Post-TAVR outcomes according to baseline MMG. 
 MMG <5 mmHg 
(n=737) 
MMG 5 to 10 mmHg 
(n=147) 
MMG ≥ 10 
mmHg 
(n=17) 
p 
Acute Kidney Injury 40 (5.4) 2 (1.4) 0 (0) 0.066 
Vascular complication 47 (6.4) 14 (9.5) 0 (0) 0.206 
Minor bleeding 91 (12.3) 19 (12.9) 3 (17.6) 0.333 
Major or life-threatening 
bleeding 
21 (2.8) 5 (3.4) 1 (5.9) 0.333 
Stroke 26 (3.5) 3 (2.0) 1 (5.9) 0.516 
Valve-in-Valve 14 (1.9) 2 (1.4) 0 (0) 0.695 
Permanent Pacemaker 
Implantation 
140 (18.9) 29 (19.7) 2 (11.8) 0.716 
New-Onset Atrial Fibrillation 67 (9.0) 17 (11.6) 1 (5.9) 0.570 
Mitral Valve intervention 2 (0.2) 1 (0.7) 1 (5.9) 0.003 
Immediate post-procedural 
Mortality 
6 (0.8) 1 (0.7) 0 (0) 0.919 
30-day Cardiovascular Mortality 19 (2.6) 1 (0.7) 1 (5.9) 0.240 
30-day All-cause Mortality 23 (3.1) 2 (1.4) 1 (5.9) 0.390 
1-year All-cause Mortality 60 (8.1) 12 (8.2) 3 (17.6) 0.573 
Values are mean±SD, median (minimum-maximum), n (%). 
 
 
